vs
Side-by-side financial comparison of American Express (AXP) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.
Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $18.9M, roughly 1.1× American Express). American Express runs the higher net margin — 15.7% vs -66.3%, a 82.0% gap on every dollar of revenue. On growth, American Express posted the faster year-over-year revenue change (11.4% vs -8.7%). Over the past eight quarters, Pulmonx Corp's revenue compounded faster (-0.5% CAGR vs -95.6%).
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...
Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.
AXP vs LUNG — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $20.6M |
| Net Profit | $3.0M | $-13.7M |
| Gross Margin | — | 77.9% |
| Operating Margin | — | -40.9% |
| Net Margin | 15.7% | -66.3% |
| Revenue YoY | 11.4% | -8.7% |
| Net Profit YoY | 15.0% | 5.5% |
| EPS (diluted) | — | $-0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.9M | $20.6M | ||
| Q4 25 | $10.9B | $22.6M | ||
| Q3 25 | $10.4B | $21.5M | ||
| Q2 25 | $10.3B | $23.9M | ||
| Q1 25 | $9.6B | $22.5M | ||
| Q4 24 | $10.0B | $23.8M | ||
| Q3 24 | $9.7B | $20.4M | ||
| Q2 24 | $9.8B | $20.8M |
| Q1 26 | $3.0M | $-13.7M | ||
| Q4 25 | $2.5B | $-10.4M | ||
| Q3 25 | $2.9B | $-14.0M | ||
| Q2 25 | $2.9B | $-15.2M | ||
| Q1 25 | $2.6B | $-14.4M | ||
| Q4 24 | $2.2B | $-13.2M | ||
| Q3 24 | $2.5B | $-14.1M | ||
| Q2 24 | $3.0B | $-15.3M |
| Q1 26 | — | 77.9% | ||
| Q4 25 | — | 77.6% | ||
| Q3 25 | — | 74.7% | ||
| Q2 25 | — | 72.1% | ||
| Q1 25 | — | 72.5% | ||
| Q4 24 | — | 74.0% | ||
| Q3 24 | — | 73.7% | ||
| Q2 24 | — | 73.7% |
| Q1 26 | — | -40.9% | ||
| Q4 25 | 28.2% | -43.8% | ||
| Q3 25 | 36.7% | -66.9% | ||
| Q2 25 | 34.4% | -62.0% | ||
| Q1 25 | 34.6% | -64.6% | ||
| Q4 24 | 27.7% | -56.5% | ||
| Q3 24 | 33.0% | -69.3% | ||
| Q2 24 | 38.6% | -75.2% |
| Q1 26 | 15.7% | -66.3% | ||
| Q4 25 | 22.5% | -46.1% | ||
| Q3 25 | 27.9% | -64.9% | ||
| Q2 25 | 28.0% | -63.6% | ||
| Q1 25 | 26.8% | -64.1% | ||
| Q4 24 | 21.8% | -55.4% | ||
| Q3 24 | 25.8% | -69.4% | ||
| Q2 24 | 30.7% | -73.7% |
| Q1 26 | — | $-0.33 | ||
| Q4 25 | $3.52 | $-0.25 | ||
| Q3 25 | $4.14 | $-0.34 | ||
| Q2 25 | $4.08 | $-0.38 | ||
| Q1 25 | $3.64 | $-0.36 | ||
| Q4 24 | $3.04 | $-0.33 | ||
| Q3 24 | $3.49 | $-0.36 | ||
| Q2 24 | $4.15 | $-0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $61.6M |
| Total DebtLower is stronger | $60.4M | $37.3M |
| Stockholders' EquityBook value | $34.0M | $45.8M |
| Total Assets | $308.9M | $120.0M |
| Debt / EquityLower = less leverage | 1.78× | 0.82× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $61.6M | ||
| Q4 25 | $742.0M | $69.8M | ||
| Q3 25 | $1.3B | $76.5M | ||
| Q2 25 | $197.0M | $75.5M | ||
| Q1 25 | $261.0M | $74.6M | ||
| Q4 24 | $221.0M | $70.9M | ||
| Q3 24 | $120.0M | $63.3M | ||
| Q2 24 | $188.0M | $63.5M |
| Q1 26 | $60.4M | $37.3M | ||
| Q4 25 | $56.4B | $37.1M | ||
| Q3 25 | $57.8B | $37.1M | ||
| Q2 25 | $58.2B | $37.1M | ||
| Q1 25 | $51.2B | $37.2M | ||
| Q4 24 | $49.7B | $37.2M | ||
| Q3 24 | $53.5B | $37.2M | ||
| Q2 24 | $51.5B | $37.2M |
| Q1 26 | $34.0M | $45.8M | ||
| Q4 25 | $33.5B | $54.1M | ||
| Q3 25 | $32.4B | $60.0M | ||
| Q2 25 | $32.3B | $69.1M | ||
| Q1 25 | $31.2B | $77.7M | ||
| Q4 24 | $30.3B | $85.8M | ||
| Q3 24 | $29.7B | $93.9M | ||
| Q2 24 | $29.5B | $101.2M |
| Q1 26 | $308.9M | $120.0M | ||
| Q4 25 | $300.1B | $129.3M | ||
| Q3 25 | $297.6B | $138.3M | ||
| Q2 25 | $295.6B | $147.2M | ||
| Q1 25 | $282.2B | $150.7M | ||
| Q4 24 | $271.5B | $162.8M | ||
| Q3 24 | $271.0B | $167.4M | ||
| Q2 24 | $272.2B | $172.6M |
| Q1 26 | 1.78× | 0.82× | ||
| Q4 25 | 1.68× | 0.69× | ||
| Q3 25 | 1.78× | 0.62× | ||
| Q2 25 | 1.80× | 0.54× | ||
| Q1 25 | 1.64× | 0.48× | ||
| Q4 24 | 1.64× | 0.43× | ||
| Q3 24 | 1.80× | 0.40× | ||
| Q2 24 | 1.74× | 0.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
LUNG
Segment breakdown not available.
